Top

Published in:

01-08-2016 | Clinical Study

Impact of IDH1 mutation status on outcome in clinical trials for recurrent glioblastoma

Authors: Jacob J. Mandel, David Cachia, Diane Liu, Charmaine Wilson, Ken Aldape, Greg Fuller, John F. de Groot

Published in: Journal of Neuro-Oncology | Issue 1/2016

Abstract

IDH1 mutated glioblastoma (GB) has a better prognosis than IDH1 wildtype GB. However, it remains unknown whether patients (pts) with IDH1 mutated GB have a higher 6-month progression free survival (PFS6) or radiographic response (RR) rate on clinical trials for recurrence. Retrospective review of GB pts at MDACC between 2006 and 2012 identified 330 patients in recurrent GB trials. 93 patients (28 %) had either PFS6 or a complete/partial RR per RANO criteria. 49/93 (53 %) patients with PFS6 or a complete/partial RR had tumor tissue for IDH1 testing. A matched cohort of 49 patients on recurrent GB clinical trials that failed to achieve PFS6 or RR (also with tissue for IDH1 testing) was identified for comparison. IDH1 status was obtained in 92/98 (94 %) patients of which 17 (18 %) had an IDH1 mutation. PFS6 was seen in 26/49 (53 %) patients. IDH status was unknown in two of these patients. 5/24 (21 %) were IDH1 mutated compared to 5/24 (21 %) of their matched cohort without PFS6. RR was found in 47/49 (94 %) patients. IDH status was unknown in four of these patients. IDH1 mutation was present in 7/43 (16 %) patients with RR compared to 10/43 (23 %) in the matched cohort without RR (p = 0.48). Median OS for trials at first recurrence was 9.8 months for IDH1 wildtype GB vs. 19.32 months for IDH1 mutated GB (p = 0.14). IDH1 mutation status was not predictive of PFS6 or RR in recurrent GB trials for this data set. However, further examination in larger randomized prospective studies is needed.

Available only for authorised users

Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359(5):492–507CrossRefPubMed

Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10): 987–96.CrossRefPubMed

Scherer H (1940) Cerebral astrocytomas and their derivatives. Am J Cancer 40:159

Kleihues P, Ohgaki H (1999) Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro Oncol 1(1):44–51PubMedPubMedCentral

Ohgaki H, Dessen P, Jourde B et al (2004) Genetic pathways to glioblastoma: a population-based study. Cancer Res 64(19):6892–6899CrossRefPubMed

Theeler BJ, Yung WK, Fuller GN, De Groot JF (2012) Moving toward molecular classification of diffuse gliomas in adults. Neurology 79(18):1917–1926. doi:10.1212/WNL.0b013e318271f7cb CrossRefPubMedPubMedCentral

Louis DN, Perry A, Burger P (2014) International Society of Neuropathology—Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol 24(5):429CrossRefPubMed

Yan H, Parsons DW, Jin G et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360(8):765–773. doi:10.1056/NEJMoa0808710 CrossRefPubMedPubMedCentral

Parsons DW, Jones S, Zhang X et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science. 321(5897): 1807. doi:10.1126/science.1164382 CrossRefPubMedPubMedCentral

10.

Labussiere M, Sanson M, Idbaih A et al (2010) IDH1 gene mutations: a new paradigm in glioma prognosis and therapy? Oncologist. 15(2): 196–199. doi:10.1634/theoncologist.2009-0218 CrossRefPubMedPubMedCentral

11.

Ohgaki H, Kleihues P (2013) The definition of primary and secondary glioblastoma. Clin Cancer Res 19(4):764–772. doi:10.1158/1078-0432.CCR-12-3002 CrossRefPubMed

12.

Nobusawa S, Watanabe T, Kleihues P, Ohgaki H (2009) IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 15(19):6002–6007. doi:10.1158/1078-0432.CCR-09-0715 CrossRefPubMed

13.

Hartmann C, Hentschel B, Wick W et al (2010) Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 120(6):707–718. doi:10.1007/s00401-010-0781-z CrossRefPubMed

14.

Sanson M, Marie Y, Paris S et al (2009) Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27(25):4150–4154. doi:10.1200/JCO.2009.21.9832 CrossRefPubMed

15.

Wen P, Macdonald D, Reardon D et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28(11):1963–1972. doi:10.1200/JCO.2009.26.3541 CrossRefPubMed

16.

Taal W, Oosterkamp HM, Walenkamp AM et al (2014) Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol 15(9):943–953. doi:10.1016/S1470-2045(14)70314-6 CrossRefPubMed

17.

Watanabe T, Nobusawa S, Kleihues P et al (2009) IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174(4):1149–1153CrossRefPubMedPubMedCentral

18.

Rohle D, Popovici-Muller J, Palaskas N et al (2013) An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 340(6132):626–630CrossRefPubMedPubMedCentral

19.

Ichimura K, Pearson DM, Kocialkowski S et al (2009) IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 11(4):341–347. doi:10.1215/15228517-2009-025 CrossRefPubMedPubMedCentral

20.

Sonoda Y, Kumabe T, Nakamura T et al (2009) Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Sci 100(10):1996–1998. doi:10.1111/j.1349-7006.2009.01270.x CrossRefPubMed

21.

Labussiere M, Boisselier B, Mokhtari K et al (2014) Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes. Neurology 83:1200–1206CrossRefPubMed

22.

Eckel-Passow JE, Lachance DH, Molinaro AM (2015) Glioma Groups Based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 372(26):2499–2508CrossRefPubMedPubMedCentral

23.

Zou Y, Xiao Bai H, Wang Z et al (2015) Comparison of immunohistochemistry and DNA sequencing for the detection of IDH1 mutations in gliomas. Neuro Oncol 17(3):477–478. doi:10.1093/neuonc/nou351 PubMedPubMedCentral

24.

Mellai M, Piazzi A, Caldera V et al (2011) IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors. J Neurooncol 105(2):345–357CrossRefPubMed

25.

Catteau A, Girardi H, Monville F et al (2014) A new sensitive PCR assay for one-step detection of 12 IDH1/2 mutations in glioma. Acta Neuropathol Commun 2:58CrossRefPubMedPubMedCentral

26.

Loussouarn D, Le Loupp AG, Frenel JS et al (2012) Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas. Int J Oncol 40(6):2058–2062.PubMed

27.

Preusser M, Capper D, Hartmann C. (2011) Euro CNS research committe. IDH testing in diagnostic neuropathology: review and practical guideline article invited by the Euro-CNS research committee. Clin Neuropathol 30(5):217–230.CrossRefPubMed

28.

Kruser TJ, Mehta MP, Kozak KR (2016) Identification of patients who benefit from bevacizumab in high-grade glioma—an easy question turned difficult: treat the scan or the patient? J Clin Oncol 34:1281–1282CrossRefPubMed

Title: Impact of IDH1 mutation status on outcome in clinical trials for recurrent glioblastoma
Authors: Jacob J. Mandel
David Cachia
Diane Liu
Charmaine Wilson
Ken Aldape
Greg Fuller
John F. de Groot
Publication date: 01-08-2016
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 1/2016
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-016-2157-2

At a glance: The STEP trials

Springer Medicine

Impact of IDH1 mutation status on outcome in clinical trials for recurrent glioblastoma

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2016

Prevalence and profile of cognitive impairment in adult glioma: a sensitivity analysis

Quercetin blocks t-AUCB-induced autophagy by Hsp27 and Atg7 inhibition in glioblastoma cells in vitro

Osteopontin in cerebrospinal fluid as diagnostic biomarker for central nervous system lymphoma

Risk and survival outcomes of radiation-induced CNS tumors

Antidepressant use and risk of central nervous system metastasis

A phase II trial evaluating the effects and intra-tumoral penetration of bortezomib in patients with recurrent malignant gliomas